Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
The New England Journal of Medicine
•
January 08, 2026
Evolocumab lowers first major cardiovascular events
In high-risk adults without prior heart attack or stroke, evolocumab reduced first major cardiovascular events without new safety concerns. *Randomized, double-blind, placebo-controlled trial; Level 1b (OCEBM).
- Level of evidence
- Level 1b (OCEBM)
- DocG quality score
- 7.0 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
